Harrow (NASDAQ:HROW) Announces Earnings Results, Beats Estimates By $0.14 EPS

Harrow (NASDAQ:HROW) announced its quarterly earnings data on Thursday. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14, Zacks reports. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%.

Harrow Trading Up 0.8 %

NASDAQ:HROW traded up $0.22 during mid-day trading on Thursday, reaching $27.87. The company’s stock had a trading volume of 394,681 shares, compared to its average volume of 489,383. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The stock has a market cap of $992.59 million, a P/E ratio of -29.65 and a beta of 0.69. The company’s fifty day simple moving average is $29.17 and its two-hundred day simple moving average is $38.18. Harrow has a twelve month low of $9.86 and a twelve month high of $59.23.

Analyst Ratings Changes

HROW has been the topic of several recent analyst reports. B. Riley lowered their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th. HC Wainwright reaffirmed a “buy” rating and set a $57.00 price target on shares of Harrow in a research note on Tuesday, March 18th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.